PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18987590-5	2008	In this in vitro study, 7-MEOTA acts as stronger inhibitor of AChE and in this way could be more favorable for treatment of cognitive manifestation of AD.	7-methoxytacrine	24-31	acetylcholinesterase (Cartwright blood group)	Homo sapiens	62-66	
29067789-1	2018	The objective of this study was to elucidate the pharmacokinetics and metabolite formation of newly developed non-selective AChE/BChE 7-MEOTA-donepezil-like inhibitors for potential therapeutic use in Alzheimer"s disease (AD) patients.	7-methoxytacrine	134-141	acetylcholinesterase (Cartwright blood group)	Homo sapiens	124-128	
25504063-4	2015	The presented study investigated whether 7-methoxytacrine (7-MEOTA) and 7-MEOTA-donepezil derivatives can act as central and peripheral reversible AChE inhibitors and simultaneously antagonize muscarinic and nicotinic receptors.	7-methoxytacrine	41-57	acetylcholinesterase (Cartwright blood group)	Homo sapiens	147-151	
28601645-2	2017	The newly synthesized derivatives 9a-d have shown higher activity against human AChE (hAChE) compared with 7-MEOTA as the standard drug.	7-methoxytacrine	107-114	acetylcholinesterase (Cartwright blood group)	Homo sapiens	80-84	
28601645-3	2017	Among them derivative 9b exhibited the most potent acetylcholinesterase inhibitory activity, with an IC50 value of 5.85muM compared with 7-MEOTA (IC50=15muM).	7-methoxytacrine	137-144	acetylcholinesterase (Cartwright blood group)	Homo sapiens	51-71	
28788095-3	2017	One such compound, namely 7-methoxytacrine (7-MEOTA), exhibits an intriguing profile, having suppressed hepatotoxicity and concomitantly retaining AChE inhibition properties.	7-methoxytacrine	26-42	acetylcholinesterase (Cartwright blood group)	Homo sapiens	147-151	
28788095-3	2017	One such compound, namely 7-methoxytacrine (7-MEOTA), exhibits an intriguing profile, having suppressed hepatotoxicity and concomitantly retaining AChE inhibition properties.	7-methoxytacrine	44-51	acetylcholinesterase (Cartwright blood group)	Homo sapiens	147-151	
25504063-4	2015	The presented study investigated whether 7-methoxytacrine (7-MEOTA) and 7-MEOTA-donepezil derivatives can act as central and peripheral reversible AChE inhibitors and simultaneously antagonize muscarinic and nicotinic receptors.	7-methoxytacrine	59-66	acetylcholinesterase (Cartwright blood group)	Homo sapiens	147-151	
25036600-2	2014	The most potent AChE inhibitor was found to be homodimeric tacrine derivative 14a, which demonstrated an IC50 value of 2 nM; this value indicates an activity rate which is 250-times higher than that of tacrine 1 and 7500-times higher than 7-MEOTA 15, the compounds which were used as standards in the study.	7-methoxytacrine	239-246	acetylcholinesterase (Cartwright blood group)	Homo sapiens	16-20	
23429378-2	2013	The compounds were prepared based on the multi-target-directed ligand strategy with different linker lengths (n = 2-8) joining the well-known NMDA antagonist adamantine and the hAChE inhibitor 7-methoxytacrine (7-MEOTA).	7-methoxytacrine	193-209	acetylcholinesterase (Cartwright blood group)	Homo sapiens	177-182